Last updated: July 27, 2026
AstraZeneca LP v. Mylan Inc. (1:15-cv-00202) Litigation Summary: What Claims Were at Issue, Procedural Posture, and IP Exposure
Executive summary
- Case: AstraZeneca LP v. Mylan Inc., 1:15-cv-00202 (filed 2015).
- Core dispute: Patent infringement allegations tied to AstraZeneca’s marketed product(s) against Mylan’s ANDA-led generic launch efforts (typical Hatch-Waxman structure for this docket type).
- What matters for strategy: The case outcome (including any Markman, final judgment, or settlement) determines whether Mylan’s ANDA could proceed immediately, launch on a partial code, or be blocked until patent expiry or other regulatory triggers.
- Actionable litigation lens: Identify (1) asserted patent numbers, (2) whether the court resolved validity, noninfringement, or both, (3) whether there was a stipulated dismissal after settlement, and (4) any remaining patents not disposed of in the docket.
No further litigation specifics can be provided because the record needed to produce an accurate, patent-level litigation summary (asserted patent list, claim construction outcomes, infringement/invalidity holdings, and terminal procedural events) is not available in the prompt.
What patents were asserted in AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
A litigation summary requires the exact asserted patent numbers and which claims were pursued. Without the case pleadings (complaint and infringement contentions) and the docket entries that list asserted patents, any patent identification would be speculative.
Related patent estate questions this docket should answer
- Which patents were composition, method-of-use, formulation, or manufacturing?
- Were patents asserted under 35 U.S.C. § 271(e)(2) via ANDA notice?
- Were there counterclaims for invalidity (anticipation/obviousness/§112)?
What was the procedural history of AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
A defensible procedural timeline requires docket facts: filing date, scheduling orders, claim construction briefing, hearing dates, dispositive motion dates, trial dates (if any), and the final judgment or settlement entry.
Procedural milestones typically decisive in ANDA patent cases
- Rule 12/59 motions (rare for early ANDA cases but possible)
- Markman (claim construction) outcomes
- Summary judgment on infringement and/or invalidity
- Final judgment and appeal posture (Federal Circuit transfer, if applicable)
- Consent judgment / dismissal after settlement
How did the court rule on infringement and invalidity in AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
To analyze IP exposure, the summary must state:
- which asserted claims were found infringing
- which claims were held invalid
- whether the court ruled on noninfringement or no induced/ contributory infringement
- whether any patents were dismissed as moot
Without the judgment or order text, this cannot be stated accurately.
Was there a settlement or dismissal in AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
Settlement analysis needs evidence from the docket, including:
- dismissal with/without prejudice
- whether it was tied to a stipulated order
- whether there was an agreed launch date
- any territory limits, approval conditions, or design-around commitments
Without docket disposition details, any characterization would be unreliable.
What is the Orange Book and FDA status impact from AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
A litigation-driven regulatory analysis requires:
- the FDA NDA/ANDA application number
- the Orange Book listed patents and their expiration dates
- whether the litigation covered listed patents or only a subset
- whether Mylan was pursuing a carved-out or design-around path
No Orange Book data is included in the prompt, so the FDA exclusivity and patent blocking implications cannot be quantified.
When does AstraZeneca’s exclusivity or asserted patents expire relative to Mylan’s generic launch risk?
A launch-risk timeline must anchor on:
- asserted patent expiry (including any PTA adjustments)
- any pediatric exclusivity (if applicable)
- statutory exclusivity and any trial-related extensions
- any negotiated settlement trigger dates
These inputs are not present in the prompt.
What generic entry risks exist for Mylan if AstraZeneca’s patents were upheld in AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
Risk depends on the final holdings:
- upheld patents mean FDA approval can be blocked until expiry or carve-out
- invalidated patents can remove barriers for immediate approval
- mixed outcomes can lead to partial launch against specific strengths/forms
Because the outcome is not provided, risk cannot be mapped.
How does this case compare with other AstraZeneca vs. generic ANDA litigations?
Comparative analysis needs:
- product identity
- asserted patent families
- jurisdictions and claim overlap
- whether courts issued consistent constructions
Without case-specific facts, comparison would be generic and not useful for decision-making.
Key Takeaways
- Case identified: AstraZeneca LP v. Mylan Inc., 1:15-cv-00202.
- Patent-level and outcome-level analysis cannot be completed from the provided input because the prompt lacks the asserted patent list, order/judgment text, and docket disposition necessary to summarize litigation with accuracy.
FAQs
- What is the docket’s final disposition in AstraZeneca LP v. Mylan Inc. (1:15-cv-00202)?
- Which AstraZeneca patents were asserted under 35 U.S.C. § 271(e)(2) in this case?
- Did the court issue a Markman order that narrowed the asserted claims?
- Did the case end in a settlement that set a launch date for Mylan?
- How does the case outcome affect FDA approval under Hatch-Waxman for Mylan’s ANDA?
References
- None provided by the prompt.
